Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 139
Filtrar
2.
Brasília; Brasil. Ministério da Saúde; 2022.
Monografia em Português | LILACS, ColecionaSUS | ID: biblio-1390710

RESUMO

Este plano define as diretrizes para implementação da ação, com a finalidade de orientar as SES e SMS envolvidas, no intuito de subsidiar no planejamento, implementação e operacionalização da Estratégia.


Assuntos
Humanos , Programas de Imunização/métodos , Controle Sanitário de Fronteiras , Vigilância em Saúde Pública/métodos , COVID-19/prevenção & controle , Brasil/epidemiologia
3.
Value Health ; 24(10): 1391-1399, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34593161

RESUMO

OBJECTIVES: Incremental cost-effectiveness analyses may inform the optimal choice of healthcare interventions. Nevertheless, for many vaccines, benefits fluctuate with incidence levels over time. Reevaluating a vaccine after it has successfully decreased incidences may eventually cause a disease resurgence if switching to a vaccine with lower indirect benefits. Decisions may successively alternate between vaccines alongside repeated rises and falls in incidence and when indirect effects from historic use are ignored. Our suggested proposal aims to prevent suboptimal decision making. METHODS: We used a conceptual model of demand to illustrate alternating decisions between vaccines because of time-varying levels of indirect effects. Similar to the concept of subsidies, we propose internalizing the indirect effects achievable with vaccines. In a case study over 60 years, we simulated a hypothetical 10-year reevaluation of 2 oncogenic human papillomavirus vaccines, of which only 1 protects additionally against anogenital warts. RESULTS: Our case study showed that the vaccine with additional warts protection is initially valued higher than the vaccine without additional warts protection. After 10 years, this differential decreases because of declines in warts incidence, which supports switching to the nonwarts vaccine that causes a warts resurgence eventually. Instead, pricing the indirect effects separately supports continuing with the warts vaccine. CONCLUSIONS: Ignoring how the observed incidences depend on the indirect effects achieved with a particular vaccine may lead to repeated changes in vaccines at successive reevaluations, with unintended resurgences, economic inefficiencies, and eroding vaccine confidence. We propose internalizing indirect effects to prevent vaccines falling victim to their own success.


Assuntos
Análise Custo-Benefício/métodos , Programas de Imunização/métodos , Fatores de Tempo , Análise Custo-Benefício/estatística & dados numéricos , Humanos , Programas de Imunização/normas , Programas de Imunização/estatística & dados numéricos
4.
Lancet Infect Dis ; 21(12): 1747-1756, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34339639

RESUMO

BACKGROUND: In Australia, the government-funded human papillomavirus (HPV) vaccination programme was introduced in April, 2007, for girls and young women, and in February, 2013, for boys. As of Dec 31, 2018, all Australian-born female individuals younger than 38 years and male individuals younger than 21 years have been eligible for the free quadrivalent or nonavalent HPV vaccine. We aimed to examine the trends in genital wart diagnoses among Australian-born female and heterosexual male individuals who attended sexual health clinics throughout Australia before and after the introduction of the gender-neutral HPV vaccination programme in February, 2013. METHODS: We did a serial cross-sectional analysis of genital wart diagnoses among Australian-born female and heterosexual male individuals attending a national surveillance network of 35 clinics between Jan 1, 2004, and Dec 31, 2018. We calculated prevalence ratios of genital warts, using log-binomial regression models, for the female-only vaccination period (July 1, 2007, to Feb 28, 2013), gender-neutral vaccination period (March 1, 2013, to Dec 31, 2018), and the whole vaccination period (July 1, 2007, to Dec 31, 2018) compared with the pre-vaccination period (Jan 1, 2004, to June 30, 2007). FINDINGS: We included 121 038 men and 116 341 women in the analysis. Overall, we observed a 58% reduction (prevalence ratio 0·42, 95% CI 0·40-0·44) in genital wart diagnoses in female individuals and a 45% reduction (0·55, 0·53-0·57) in genital wart diagnoses in heterosexual male individuals after the introduction of the vaccination programme in 2007. The largest reduction in genital warts was observed in younger individuals, and there was a decreasing magnitude of reduction with increasing age (80%, 72%, 61%, 41%, and 16% reductions in female individuals aged 15-20 years, 21-25 years, 26-30 years, 31-35 years, and ≥36 years, respectively; 70%, 61%, 49%, 37%, and 29% reductions in male individuals aged 15-20 years, 21-25 years, 26-30 years, 31-35 years, and ≥36 years, respectively). Significant reductions observed in female individuals (0·32, 0·28-0·36) and male individuals (0·51, 0·43-0·61) aged 15-20 years in the female-only vaccination period were followed by a more substantial reduction in female individuals (0·07, 0·06-0·09) and male individuals (0·11, 0·08-0·15) aged 15-20 years in the gender-neutral vaccination period. INTERPRETATION: The national gender-neutral HPV vaccination programme has led to substantial and ongoing reduction in genital warts among Australian female and heterosexual male individuals, with a marked reduction in young individuals who received the vaccine at school. FUNDING: Seqirus Australia and the Australian Government Department of Health.


Assuntos
Condiloma Acuminado/epidemiologia , Condiloma Acuminado/prevenção & controle , Programas de Imunização/métodos , Vacinas contra Papillomavirus/administração & dosagem , Adolescente , Adulto , Austrália/epidemiologia , Estudos Transversais , Feminino , Heterossexualidade , Humanos , Masculino , Prevalência , Vigilância de Evento Sentinela , Adulto Jovem
5.
Proc Natl Acad Sci U S A ; 118(30)2021 07 27.
Artigo em Inglês | MEDLINE | ID: mdl-34234013

RESUMO

Development of effective vaccines against coronavirus disease 2019 (COVID-19) is a global imperative. Rapid immunization of the entire human population against a widespread, continually evolving, and highly pathogenic virus is an unprecedented challenge, and different vaccine approaches are being pursued. Engineered filamentous bacteriophage (phage) particles have unique potential in vaccine development due to their inherent immunogenicity, genetic plasticity, stability, cost-effectiveness for large-scale production, and proven safety profile in humans. Herein we report the development and initial evaluation of two targeted phage-based vaccination approaches against SARS-CoV-2: dual ligand peptide-targeted phage and adeno-associated virus/phage (AAVP) particles. For peptide-targeted phage, we performed structure-guided antigen design to select six solvent-exposed epitopes of the SARS-CoV-2 spike (S) protein. One of these epitopes displayed on the major capsid protein pVIII of phage induced a specific and sustained humoral response when injected in mice. These phage were further engineered to simultaneously display the peptide CAKSMGDIVC on the minor capsid protein pIII to enable their transport from the lung epithelium into the systemic circulation. Aerosolization of these "dual-display" phage into the lungs of mice generated a systemic and specific antibody response. In the second approach, targeted AAVP particles were engineered to deliver the entire S protein gene under the control of a constitutive CMV promoter. This induced tissue-specific transgene expression, stimulating a systemic S protein-specific antibody response in mice. With these proof-of-concept preclinical experiments, we show that both targeted phage- and AAVP-based particles serve as robust yet versatile platforms that can promptly yield COVID-19 vaccine prototypes for translational development.


Assuntos
Bacteriófagos/genética , Vacinas contra COVID-19/administração & dosagem , COVID-19/prevenção & controle , Programas de Imunização , Administração por Inalação , Animais , Vacinas contra COVID-19/química , Vacinas contra COVID-19/imunologia , Dependovirus/genética , Armazenamento de Medicamentos , Feminino , Programas de Imunização/métodos , Imunogenicidade da Vacina , Camundongos , Camundongos Endogâmicos BALB C , Estudo de Prova de Conceito , Temperatura
6.
Pediatr Infect Dis J ; 40(8): 774-781, 2021 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-34250977

RESUMO

BACKGROUND: Incorporating dengue vaccination within existing vaccination programs could help improve dengue vaccine coverage. We assessed the immunogenicity and safety of a quadrivalent human papillomavirus (HPV) vaccine administered concomitantly or sequentially with a tetravalent dengue vaccine (CYD-TDV) in healthy children 9-13 years of age in Malaysia. METHODS: In this phase IIIb, open-label, multicenter study (NCT02993757), participants were randomized 1:1 to receive 3 CYD-TDV doses 6 months apart and 2 doses of quadrivalent HPV vaccine concomitantly with, or 1 month before (sequentially), the first 2 CYD-TDV doses. Only baseline dengue-seropositive participants received the 3 doses. Antibody levels were measured at baseline and 28 days after each injection using an enzyme-linked immunosorbent assay for HPV-6, -9, -16 and -18, and the 50% plaque reduction neutralization test for the 4 dengue serotypes; immunogenicity results are presented for baseline dengue-seropositive participants. Safety was assessed throughout the study for all participants. RESULTS: At baseline, 197 of 528 (37.3%) randomized participants were dengue-seropositive [n = 109 (concomitant group) and n = 88 (sequential group)]. After the last HPV vaccine dose, antibody titers for HPV among baseline dengue-seropositive participants were similar between treatment groups, with between-group titer ratios close to 1 for HPV-6 and 0.8 for HPV-11, -16, and -18. After CYD-TDV dose 3, dengue antibody titers were similar between treatment groups for all serotypes [between-group ratios ranged from 0.783 (serotype 2) to 1.07 (serotype 4)]. No safety concerns were identified. CONCLUSIONS: The immunogenicity and safety profiles of CYD-TDV and quadrivalent HPV vaccines were unaffected when administered concomitantly or sequentially in dengue-seropositive children.


Assuntos
Vacinas contra Dengue/administração & dosagem , Vacina Quadrivalente Recombinante contra HPV tipos 6, 11, 16, 18/administração & dosagem , Imunogenicidade da Vacina , Segurança do Paciente , Vacinas Combinadas/administração & dosagem , Adolescente , Criança , Vacinas contra Dengue/imunologia , Feminino , Vacina Quadrivalente Recombinante contra HPV tipos 6, 11, 16, 18/imunologia , Humanos , Programas de Imunização/métodos , Malásia/epidemiologia , Masculino , Vacinas Combinadas/imunologia
7.
Thromb Haemost ; 121(8): 992-1007, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34169495

RESUMO

BACKGROUND: One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis. MANAGEMENT: Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic. CURRENT ISSUES: The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments. PERSPECTIVES: There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA). CONCLUSION: The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.


Assuntos
COVID-19/epidemiologia , COVID-19/prevenção & controle , Saúde Pública , COVID-19/diagnóstico , Teste para COVID-19/métodos , Vacinas contra COVID-19/uso terapêutico , Gerenciamento Clínico , Humanos , Programas de Imunização/métodos , Pandemias/prevenção & controle , Saúde Pública/métodos , Medição de Risco , SARS-CoV-2/isolamento & purificação
8.
PLoS One ; 16(6): e0252310, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34166437

RESUMO

OBJECTIVES: To assess the success of a human papillomavirus (HPV) vaccination program among adolescent girls aged 9-14 years in Haiti and to understand predictors of completion of a two-dose HPV vaccination series. METHODS: Data collection was conducted during HPV vaccination campaigns in Port-au-Prince between August 2016 and April 2017. Descriptive statistics and logistic regression models were used to examine characteristics associated with vaccination series completion of school based and non-school based vaccination delivery modalities. RESULTS: Of the 2,445 adolescent girls who participated in the awareness program, 1,994 participants (1,307 in non-school program, 687 in school program) received the first dose of the vaccine; 1,199 (92%) in the non-school program and 673 (98%) in the school program also received the second dose. Menarche (OR: 1.87; 95% CI, 1.11-3.14), if the participant was a prior patient at the GHESKIO clinics (OR: 2.17; 95% CI, 1.32-3.58), and participating in the school-based program (OR: 4.17; 95% CI, 2.14-8.12) were significantly associated with vaccination completion. CONCLUSIONS: Vaccination in school- and non-school-based settings was successful, suggesting that a nationwide HPV vaccination campaign using either approach would be successful using either approach.


Assuntos
Programas de Imunização/métodos , Papillomaviridae/efeitos dos fármacos , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Aceitação pelo Paciente de Cuidados de Saúde , Instituições Acadêmicas/estatística & dados numéricos , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Idoso , Criança , Serviços de Saúde Comunitária , Feminino , Haiti/epidemiologia , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Papillomaviridae/imunologia , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/virologia , Adulto Jovem
9.
Int J Cancer ; 149(1): 191-199, 2021 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-33586169

RESUMO

Since 2008, girls in British Columbia (BC), Canada, have been offered HPV vaccination through a school-based, publicly funded immunization program. The oldest birth cohort eligible for the vaccination program was born in 1994 and uptake is on average 63%. To evaluate the impact of the HPV vaccine in BC, ecological trends in cervical intraepithelial neoplasia (CIN) rates were assessed in young women before and after the implementation of the HPV vaccination program. Information on all Pap smears and histopathological abnormalities, in calendar years 2004-2017 in women 16-28 years of age in BC were obtained from the population-based BC Cancer Cervix Screening Program database. Rates of CIN 2 and 3 were calculated as the number of cases divided by the number of cytology specimens for that period. Rate ratios (RR) were calculated by negative binomial piecewise regression. Age-centered incidence rates of CIN 2 and 3 in BC declined significantly among women 16-23 years of age after HPV vaccine introduction compared to before vaccine introduction. The overall reduction postvaccination for CIN2 and 3 in women 16-23 years was respectively 62% (95% CI 54-68%) and 65% (95% CI 58-71%). Age-specific rates for CIN2 significantly declined for those 18-22 years of age and for those 19, 20 and 23 years of age for CIN3. Among women 24-28 years of age no decline in CIN2 and 3 rate over time was observed. The observed reduction in CIN 2 and 3 rates since the introduction of the school-based HPV vaccine program might illustrate the population impact of the BC provincial school-based HPV vaccination program.


Assuntos
Programas de Imunização/métodos , Papillomaviridae/efeitos dos fármacos , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Displasia do Colo do Útero/prevenção & controle , Neoplasias do Colo do Útero/prevenção & controle , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Colúmbia Britânica/epidemiologia , Feminino , Seguimentos , Humanos , Incidência , Papillomaviridae/imunologia , Infecções por Papillomavirus/complicações , Infecções por Papillomavirus/virologia , Prognóstico , Instituições Acadêmicas , Neoplasias do Colo do Útero/epidemiologia , Neoplasias do Colo do Útero/virologia , Esfregaço Vaginal/métodos , Adulto Jovem , Displasia do Colo do Útero/epidemiologia , Displasia do Colo do Útero/virologia
10.
Pan Afr Med J ; 36: 340, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33193993

RESUMO

INTRODUCTION: globally, by 2020 the paralytic poliomyelitis disease burden decreased to over 99% of the reported cases in 1988 when resolution 41.8 was endorsed by the World Health Assembly (WHA) for global polio eradication. It is clearly understood that, if there is Wild Poliovirus (WPV) and circulating Vaccines Derived Poliovirus (cVDPV) in the world, no country is safe from polio outbreaks. All countries remain at high risk of re-importation depending on the level of the containment of the types vaccine withdrawn, the laboratory poliovirus isolates, and the population immunity induced by the vaccination program. In this regard, countries to have polio outbreak preparedness and response plans, and conducting the polio outbreak simulation exercises for these plans remain important. METHODS: we conducted a cross-section qualitative study to review to 8 countries conducted polio outbreak simulation exercises in the East and Southern Africa from 2016 to 2018. The findings were categorized into 5 outbreak response thematic areas analyzed qualitatively and summarized them on their strengths and weaknesses. RESULTS: we found out that, most countries have the overall technical capacities and expertise to deal with outbreaks to a certain extent. Nevertheless, we noted that the national polio outbreak preparedness and response plans were not comprehensive enough to provide proper guidance in responding to outbreaks. The guidelines were inadequately aligned with the WHO POSOPs, and IHR 2005. Additionally, most participants who participated in the simulation exercises were less familiar with their preparedness and response plans, the WHO POSOPs, and therefore reported to be sensitized. CONCLUSION: we also realized that, in all countries where the polio simulation exercise conducted, their national polio outbreak preparedness and response plan was revised to be improved in line with the WHO POSOPs and IHR 2005. we, therefore, recommend the polio outbreak simulation exercises to be done in every country with an interval of 3-5 years.


Assuntos
Defesa Civil/métodos , Poliomielite/epidemiologia , Poliomielite/terapia , Treinamento por Simulação/métodos , África Subsaariana/epidemiologia , Defesa Civil/organização & administração , Simulação por Computador , Estudos Transversais , Erradicação de Doenças , Surtos de Doenças , Estudos de Avaliação como Assunto , Saúde Global/normas , Implementação de Plano de Saúde/organização & administração , Implementação de Plano de Saúde/normas , História do Século XXI , Humanos , Programas de Imunização/métodos , Programas de Imunização/organização & administração , Programas de Imunização/normas , Programas Nacionais de Saúde/organização & administração , Programas Nacionais de Saúde/normas , Vacinas contra Poliovirus/provisão & distribuição , Vacinas contra Poliovirus/uso terapêutico , Vigilância da População , Estudos Retrospectivos , Medição de Risco , Treinamento por Simulação/organização & administração , Treinamento por Simulação/normas , Estoque Estratégico/métodos , Estoque Estratégico/organização & administração
11.
Obstet Gynecol ; 136(5): 1006-1015, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-33030866

RESUMO

OBJECTIVE: To evaluate the result of an inpatient postpartum human papillomavirus (HPV) immunization pilot program in a diverse, low-income patient population from an urban, hospital-based obstetrics and gynecology clinic. METHODS: In this cohort study, we present results from the first 2 years of the inpatient postpartum HPV immunization program, in which vaccine-eligible postpartum women were identified and immunized during their hospital stays. The program was implemented after educational outreach with prenatal and postpartum clinicians and nurses. Associations between receipt of the HPV vaccine as an inpatient and the characteristics of patients, and the likelihood of and missed opportunities for receiving a subsequent dose of the HPV vaccine as an outpatient were determined using logistic regression, time-to-event analyses, chi-squared tests and t-tests. RESULTS: From April 11, 2017, to April 10, 2019, 394 (59.2%) of 666 postpartum women were eligible for the inpatient postpartum HPV immunization program. The majority (265/394, 67.3%) received the immunization pilot program HPV dose; 36 of those 265 (13.6%) completed the series with that dose. Among women due for additional doses after hospital discharge, those who received the inpatient dose were more likely to receive a subsequent outpatient dose (138/229) than were those who did not receive an inpatient dose (39/129; hazard ratio 2.51, 95% CI 1.76-3.58). On average, there were 30.7 fewer (95% CI 5.8-55.6, P<.02) missed opportunities for subsequent outpatient doses for every 100 eligible visits among women who received the inpatient dose, compared with women who did not. By the end of the study, the proportion of women who had completed the vaccine series was higher among women who received the inpatient dose (95/265, 35.8%) than in those who did not (12 out 129, 9.3%; odds ratio 5.45, 95% CI 2.86-10.38). CONCLUSION: The inpatient postpartum HPV immunization program was associated with increased rates of immunization and addressed a previously missed opportunity. Inpatient immunization programs can serve as a critical way to address gaps in vaccine uptake.


Assuntos
Programas de Imunização/estatística & dados numéricos , Pacientes Internados/estatística & dados numéricos , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Cuidado Pós-Natal/estatística & dados numéricos , Adulto , Distribuição de Qui-Quadrado , Feminino , Hospitais Urbanos , Humanos , Programas de Imunização/métodos , Programas de Imunização/normas , Modelos Logísticos , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Cuidado Pós-Natal/métodos , Cuidado Pós-Natal/normas , Pobreza/estatística & dados numéricos , Gravidez , Avaliação de Programas e Projetos de Saúde , Melhoria de Qualidade , Adulto Jovem
12.
Rev. cub. inf. cienc. salud ; 31(2): e1515, abr.-jun. 2020. tab
Artigo em Português | LILACS, CUMED | ID: biblio-1138855

RESUMO

O estudo teve o objetivo de analisar o Sistema de Informação de Imunizações web do Brasil sob a ótica das heurísticas de usabilidade. Trata-se de um estudo descritivo, com abordagem qualitativa sobre a avaliação de usabilidade de um novo software sobre o Programa Nacional de Imunizações, com base nas dez Heurísticas de Nielsen. Participaram quatro especialistas da área de Tecnologia da Informação, com conhecimento sobre usabilidade e Programa de Imunizações. Os dados foram tratados pela análise de Conteúdo, na modalidade Temático-Categorial. O sistema proporciona, de um lado, facilidade de acesso aos usuários, podendo ser acessado de qualquer lugar e momento, desde que tenha conectividade com a internet; e de outro, apresenta problemas de usabilidade quanto à percepção de localização do usuário no percurso feito dentro do próprio sistema; apresenta entraves em relação a padronização tanto das telas, quanto dos recursos disponibilizados pelo sistema, além de falhas e duplicidade de comandos, que dificultam o registro e acesso às informações. Os problemas elucidados na avaliação de usabilidade do Sistema de Informação de Imunizações do Brasil poderão embasar melhorias nas novas versões de atualizações(AU)


Este estudio tuvo como objetivo analizar el sistema de información de inmunizaciones en Brasil desde la perspectiva de las heurísticas de usabilidad. Se realizó un estudio descriptivo, con un enfoque cualitativo, sobre la evaluación de la usabilidad de un nuevo software en el programa nacional de inmunización, basado en las diez heurísticas de Nielsen. Participaron cuatro especialistas del área de Tecnología de la Información, con conocimiento sobre usabilidad y el programa de inmunizaciones. Los datos fueron tratados mediante análisis de contenido, en la modalidad temático-categorial. El sistema proporciona facilidad de acceso a los usuarios, al que se puede acceder desde cualquier lugar y en cualquier momento, siempre que tenga conectividad a internet, y presenta problemas de usabilidad con respecto a la percepción del usuario de la ubicación en la ruta tomada dentro del propio sistema. Presenta obstáculos en relación con la estandarización de ambas pantallas y los recursos puestos a disposición por el sistema, además de fallas y duplicación de comandos, que dificultan el registro y el acceso a la información. Los problemas aclarados en la evaluación de usabilidad del sistema de información de inmunizaciones en Brasil pueden respaldar mejoras en nuevas versiones de actualizaciones(AU)


The purpose of the study was to analyze the Brazilian immunization information system from the perspective of usability heuristics. A descriptive qualitative study was conducted evaluating the usability of a new software for the national immunization program based on the ten Nielsen's heuristics. Four specialists from the Information Technology area participated who were knowledgeable about usability and the immunization program. The data were processed by thematic-categorial content analysis. The system provides users with easy access from any place at any time, as long as they can connect to the Internet, and presents usability problems related to perception by users of their place along the route taken within the system itself. It also poses hurdles concerning standardization of the two screens and the resources made available by the system, besides failures and duplication of commands, which hampers the recording of and access to information. The problems clarified in the evaluation of the usability of the Brazilian immunization information system may serve to improve new updated versions(AU)


Assuntos
Humanos , Masculino , Feminino , Diagnóstico da Situação de Saúde , Programas de Imunização/métodos , Registros Eletrônicos de Saúde , Heurística , Brasil , Epidemiologia Descritiva , Estudos de Avaliação como Assunto
13.
Pediatrics ; 145(5)2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32253263

RESUMO

BACKGROUND: Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear. METHODS: In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: N = 30 616 in 123 practices; CO: N = 31 502 in 80 practices) were randomly assigned to receive 0, 1, 2, or 3 IIS C-R/R autodialer messages per vaccine dose. We assessed HPV vaccine receipt via the IIS, calculated intervention costs, and compared HPV vaccine series initiation and completion rates across study arms. RESULTS: In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively). CONCLUSIONS: IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado.


Assuntos
Programas de Imunização/tendências , Imunização/tendências , Vacinas contra Papillomavirus/administração & dosagem , Sistemas de Alerta/tendências , Vacinação/tendências , Adolescente , Criança , Colorado/epidemiologia , Feminino , Humanos , Imunização/métodos , Programas de Imunização/métodos , Masculino , New York/epidemiologia , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/prevenção & controle , Vacinação/métodos
16.
Vaccine ; 38(3): 680-689, 2020 01 16.
Artigo em Inglês | MEDLINE | ID: mdl-31679861

RESUMO

School-based vaccination (SBV) and checking students' vaccination records at school have the potential to optimize vaccination coverage among school-aged children. The primary aim of this paper is to describe adoption of SBV by countries from 2008 to 2017, including target age groups and vaccines delivered in 2017, as reported annually through the World Health Organization (WHO)-United Nations Children's fund (UNICEF) Joint Reporting Form (JRF). Expanding upon previous analyses, country-specific rates of primary school enrollment and home-based record (HBR) ownership were linked to the WHO-UNICEF JRF data, to identify countries with high potential to implement vaccination record checks at school. The proportion of countries reporting delivery of at least one routinely recommended vaccine dose in school settings increased from 95 (of 163 reporting; 58%) in 2008 to 108 (of 181 reporting; 60%) in 2017. The 13 additional countries that reported using SBV in 2017 were among 31 countries for which SBV data from the JRF were unavailable in 2017. The most common antigens delivered through SBV in 2017 were tetanus (94 countries), diphtheria (89 countries), and human papillomavirus (52 countries). Among 93 countries with data available for net primary school enrollment and HBR ownership, 52 (56%) countries had both ≥80% net primary school enrollment and ≥80% of children aged 12-23 months ever owning an HBR; 33 (63%) of these used SBV. If not already doing so, these 33 countries represent an opportunity to introduce routine checking of vaccination status at entry to, or during primary school. With the growing number of new vaccines and booster doses of childhood vaccines targeting school-age children, implementation of SBV and checking of student vaccination records at school may help improve vaccination coverage; however, additional data are needed to assess global prevalence of checking vaccination status at school and to identify factors facilitating optimal implementation of this strategy.


Assuntos
Atenção à Saúde/tendências , Saúde Global/tendências , Serviços de Saúde Escolar/tendências , Cobertura Vacinal/tendências , Vacinação/tendências , Criança , Pré-Escolar , Atenção à Saúde/métodos , Feminino , Humanos , Programas de Imunização/métodos , Programas de Imunização/tendências , Lactente , Masculino , Nações Unidas/tendências , Vacinação/métodos , Cobertura Vacinal/métodos , Organização Mundial da Saúde
18.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 38: e2018120, 2020. tab, graf
Artigo em Inglês, Português | LILACS, SES-SP | ID: biblio-1136733

RESUMO

ABSTRACT Objective: To evaluate the trend of hospitalization for acute bronchiolitis in infants under one year of age, in the past eight years and after the implementation of the palivizumab immunization program in Brazil. Methods: The study is a retrospective analysis of data on infants younger than one year of age, who were hospitalized with acute bronchiolitis between 2008 and 2015 in Brazil. The Brazilian National Health System database was used. The rates of hospitalization in the pre-implementation (2008-2012) and post-implementation (2014-2015) periods of the palivizumab immunization program were evaluated. The total number of admissions in the same period was used as a comparison. Results: Between January 2008 and December 2015, 263,679 hospitalizations for bronchiolitis were recorded in infants younger than one year of age, 60% represented by boys. The incidence of hospitalization for bronchiolitis increased by 49% over this period (8.5 to 12.7 per 1,000 inhabitants per year). Between 2013 and 2014, the incidence rate of hospitalization for acute bronchiolitis decreased by 8% (12.5 to 11.5 per 1,000 inhabitants per year). However, in the second year of the program, hospitalization rate increased again by 10% (12.7 per 1,000 inhabitants per years). Conclusions: Acute bronchiolitis presented increasing rates of hospitalization over the study period. Hospitalization incidence for acute bronchiolitis declined one year after the implementation of palivizumab but increased again in the second year of the program.


RESUMO Objetivo: Avaliar a tendência de hospitalização por bronquiolite aguda (BA) em lactentes menores de um ano de idade nos últimos oito anos no Brasil e, secundariamente, após a implementação do programa de imunização por palivizumabe. Métodos: Análise retrospectiva dos dados de lactentes menores de um ano de idade, hospitalizados com diagnóstico de BA entre 2008 e 2015 no Brasil, utilizando o banco de dados do Sistema Único de Saúde (SUS). Foram avaliadas as taxas de hospitalização nos períodos pré-implementação (2008-2012) e pós-implementação (2014-2015) do programa de imunização por palivizumabe. O número total de internações no mesmo período foi utilizado como comparação. Resultados: Entre janeiro de 2008 e dezembro 2015 foram registradas 263.679 internações por bronquiolite em lactentes menores de um ano de idade, 60% representado por meninos. A incidência de hospitalização por bronquiolite aumentou em 49% ao longo desse período (8,5 para 12,7 por mil ­habitantes/­ano). Entre 2013 e 2014, a taxa de incidência de hospitalização por BA diminuiu 8% (12,5 para 11,5 por mil habitantes/ano). Porém, no segundo ano do programa, a taxa de internação aumentou novamente em 10% (12,7 por mil habitantes/ano). Conclusões: A BA apresentou taxas de hospitalização crescente ao longo do período estudado. A incidência de hospitalizações de BA apresentou declínio um ano após a implementação de palivizumabe e retornou à tendência crescente no segundo ano do programa.


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Antivirais/uso terapêutico , Bronquiolite/tratamento farmacológico , Bronquiolite/epidemiologia , Palivizumab/uso terapêutico , Hospitalização/tendências , Antivirais/administração & dosagem , Vírus Sinciciais Respiratórios/imunologia , Fatores de Tempo , Brasil/epidemiologia , Bronquiolite/imunologia , Bronquiolite/virologia , Doença Aguda , Incidência , Estudos Retrospectivos , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Programas de Imunização/métodos , Palivizumab/administração & dosagem , Implementação de Plano de Saúde/métodos
19.
Rev. cuba. med. trop ; 71(3): e394, sept.-dic. 2019. tab, graf
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1093580

RESUMO

Objetivo: conocer desde la perspectiva social, los conocimientos y creencias de la población a partir del significado que las personas le atribuyen a las vacunas preventivas y al proceso de vacunación. Métodos: Se realizó un estudio exploratorio con familiares de niños de 0 a 24 meses pertenecientes al Policlínico 5 de Septiembre, municipio Playa, La Habana, que abarcó de enero a junio de 2015. Se utilizó un diseño mixto convergente o por triangulación de datos. Para la recolección de datos se utilizó la entrevista-cuestionario, entrevista a expertos y entrevista a informantes claves. Se elaboró una base de datos en Excel, la que se exportó al programa SPSS versión 19.0. En un primer momento, se realizó un análisis descriptivo, en el que se calcularon frecuencias absolutas y relativas para las variables de estudio. Para establecer las relaciones entre el nivel de conocimiento y algunas variables sociodemográficas, para el análisis de los datos cualitativos, se realizaron lecturas reiteradas de las transcripciones de las entrevistas a expertos e informantes claves y de las respuestas a las preguntas abiertas del cuestionario para la familiarización con el contenido de estos. Resultados: Se puso de manifiesto la vía institucional en la cultura de la salud que poseen los familiares con relación a las vacunas y el proceso de vacunación. Los familiares presentaban en su mayoría conocimientos insuficientes acerca de las vacunas y las enfermedades que protegen estas. No presentaban conocimientos sobre los eventos adversos graves o severos. El proceso de vacunación mostró gran significado para los familiares, asociados a experiencias positivas con este. Conclusiones: Se inicia un acercamiento a la cultura de la salud, poseída por un grupo de familiares, relativos a las vacunas preventivas y el proceso de vacunación en Cuba. Las madres refuerzan la responsabilidad de vacunar al niño/a como parte del cuidado de la salud de este. La cultura de la salud en los familiares de niños/as no incluye información distorsionada sobre las vacunas preventivas y su efectividad. Se nutre exclusivamente de la cultura científica, aunque no la reproduce en su totalidad. El proceso de vacunación es altamente valorado por los familiares, dada la importancia que le atribuyen, la confianza que tienen en el Programa Nacional de Inmunización, la satisfacción que muestran con la organización del servicio y la atención del personal de salud(AU)


Objective: to know, from the social perspective, the population´s knowledge and beliefs based on the meaning that people attribute to preventive vaccines and the vaccination process. Methods: An exploratory study was carried out with relatives of children from 0 to 24 months from "5 de Septiembre" community clinic in Playa municipality, Havana, from January to June 2015. A mixed convergent or triangulation design was used. Data collection was completed by questionnaire interview, expert interview and interview to key informants. A database was created in Excel, which was exported to the SPSS program version 19.0. Initially, a descriptive analysis was performed, in which absolute and relative frequencies were calculated for the study variables. Repeated readings were made of the transcripts of the interviews with experts and key informants and for the answers to the open questions of the questionnaire, to establish the analysis of the qualitative data, and for familiarization with their content. Results: It was shown the institutional pathway in health culture that family members have in relation to vaccines and the vaccination process. Most family members had poor knowledge about vaccines and the diseases they prevent. They did not show knowledge about serious or severe adverse events. The vaccination process showed great significance for family members, associated with positive experiences with it. Conclusions: This study initiates an approach to the health culture a group of family members had related to preventive vaccines and the vaccination process in Cuba. Mothers reinforce the responsibility of vaccinating the child as part of their child's health care. The health culture in family members of children does not include distorted information about preventive vaccines and their effectiveness. Their knowledge is fed exclusively by scientific culture, although it is entirety not reproduce. The vaccination process is highly valued by family members, given the importance they attach to it, the confidence they have in the National Immunization Program, the satisfaction they show with the organization of the service and the care of health personnel(AU)


Assuntos
Humanos , Masculino , Feminino , Programas de Imunização/métodos , Letramento em Saúde/ética , Educação da População , Recusa de Vacinação/ética
20.
Vaccine ; 37(46): 6907-6914, 2019 10 31.
Artigo em Inglês | MEDLINE | ID: mdl-31562001

RESUMO

BACKGROUND: Australia introduced a school-based human papillomavirus (HPV) vaccination program for females aged 12-13 years in 2007, with a three-year catch-up to age 26; and for boys aged 12-13 from 2013, with a two-year catch-up to age 15. This study aimed to compare the prevalence of penile HPV between teenage heterosexual males in cohorts eligible or non-eligible for the school-based male vaccination program. METHODS: Between 2014 and 2017, sexually active heterosexual males aged 17-19 were recruited from sexual health centres and community sources across Australia. Males provided a self-collected penile swab for 37 HPV genotypes using Roche Linear Array and completed a questionnaire. We calculated adjusted prevalence ratios (aPR) of HPV between males in two periods: 2014-2015 (preceding implementation of school-based male vaccination) and 2016-2017 (eligible for school-based male vaccination). Self-reported vaccine doses were confirmed with doses reported to the National HPV Vaccination Program Register. RESULTS: Overall, 152 males were recruited in 2014-2015 and 146 in 2016-2017. Numbers of female sex partners and condom use did not differ between the two periods. The prevalence of quadrivalent vaccine-preventable [4vHPV] genotypes (6/11/16/18) was low in both periods (2.6% [2014-15] versus 0.7% [2016-17]; p = 0.371; aPR 0.28 [95% CI: 0.03-2.62]). Compared with men in 2014-2015, men in 2016-2017 had a lower prevalence of any of the 37 HPV genotypes tested (21.7% versus 11.6%; aPR 0.62 [95% CI: 0.36-1.07]) and any of the 13 high-risk genotypes tested (15.8% versus 7.5%; aPR 0.59 [95% CI: 0.30-1.19]). Prevalence of low-risk HPV genotypes did not differ between the two periods. Of the males recruited in 2016-2017, 55% had received ≥1 vaccine dose. CONCLUSION: The prevalence of 4vHPV genotypes among teenage heterosexual males in both cohorts was low, presumably due to herd protection from the female-only vaccination program. Further studies are required to determine the impact of universal HPV vaccination on HPV prevalence in males.


Assuntos
Heterossexualidade/estatística & dados numéricos , Papillomaviridae/patogenicidade , Adolescente , Adulto , Austrália , Criança , Feminino , Humanos , Programas de Imunização/métodos , Masculino , Papillomaviridae/imunologia , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/imunologia , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/imunologia , Vacinas contra Papillomavirus/uso terapêutico , Prevalência , Instituições Acadêmicas/estatística & dados numéricos , Vacinação/métodos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA